Empagliflozin, an SGLT2 inhibitor, is proven safe and effective for heart attack patients, offering a new treatment option to improve outcomes.
Vous n'êtes pas connecté
A nationwide study has found that emergency medical services (EMS) agencies that adopt several critical best practices have higher survival rates among heart attack patients. Co-led by a researcher from UT Southwestern Medical Center, the study, published in JAMA Cardiology, highlights the importance of specific training methods and practices in improving outcomes for out-of-hospital cardiac […]
Empagliflozin, an SGLT2 inhibitor, is proven safe and effective for heart attack patients, offering a new treatment option to improve outcomes.
THURSDAY, Sept. 12, 2024 -- Statin therapy improves health outcomes and is cost-effective for men and women aged 70 years and older, according to a...
Researchers at Tokyo Medical and Dental University have found that the periodontal bacterium Aggregatibacter actinomycetemcomitans exacerbates...
A new GALAXY study reveals Signatera's cell-free DNA test predicts survival rates and chemotherapy benefits for colorectal cancer patients with high...
A new GALAXY study reveals Signatera's cell-free DNA test predicts survival rates and chemotherapy benefits for colorectal cancer patients with high...
Atrial fibrillation, a rapid, irregular heart beat that can lead to stroke or sudden death, is three times more common than previously thought,...
Across all species, critical skills are passed on from parents to offspring through communication. Researchers at the University Hospital Bonn (UKB)...
Across all species, critical skills are passed on from parents to offspring through communication. Researchers at the University Hospital Bonn (UKB)...
MONDAY, Sept. 9, 2024 -- Empagliflozin confers kidney-protective benefits for patients with acute myocardial infarction (MI) and an increased risk...
New report finds education investment in Nigeria and around the world critical to future success during times of economic challenges Pioneering...